$1.8393
-0.1007[-5.19%]
Last update: 9:11AM Get Real Time Here
eFFECTOR Therapeutics
(NASDAQ:EFTR)Latest News for eFFECTOR Therapeutics Stock (NASDAQ:EFTR)
eFFECTOR Therapeutics Stock (NASDAQ: EFTR)
Categories: All
Friday, April 05, 2024
Thursday, April 04, 2024
- Dow Dips Over 200 Points; RPM International Shares Fall After Q3 ResultsAvi Kapoor - Apr 4, 2024, 2:39PM
- Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionAvi Kapoor - Apr 4, 2024, 1:21PM
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga Insights - Apr 4, 2024, 12:31PM
- Nasdaq Surges 1%; ConAgra Brands Posts Upbeat EarningsAvi Kapoor - Apr 4, 2024, 11:58AM
- Cancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing DataVandana Singh - Apr 4, 2024, 10:38AM
- Dow Jumps Over 100 Points; US Jobless Claims Increase To 221,000Avi Kapoor - Apr 4, 2024, 10:02AM
- EFFECTOR Therapeutics Shares Resume TradeBenzinga Newsdesk - Apr 4, 2024, 9:52AM
- EFFECTOR Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down -83.2%Benzinga Newsdesk - Apr 4, 2024, 9:49AM
- EFFECTOR Therapeutics shares are trading lower. The company announced topline results from the primary analysis of the randomized Phase 2 KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer.Benzinga Newsdesk - Apr 4, 2024, 9:17AM
- Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga Newsdesk - Apr 4, 2024, 8:55AM
- eFFECTOR Therapeutics Announces Topline Results Of Phase 2 KICKSTART Trial Of Tomivosertib Combined With Pembrolizumab In Non-Small Cell Lung CancerBenzinga Newsdesk - Apr 4, 2024, 8:32AM
- Trading Halt: Halted at 8:25:00 a.m. ET - Trading Halt: Halt News PendingBenzinga Newsdesk - Apr 4, 2024, 8:25AM
Thursday, March 28, 2024
Monday, March 25, 2024
- eFFECTOR Therapeutics Cash, Cash Equivalents, And Short-Term Investments Totaling $18.4M As Of December 31, 2023; Anticipates That It Will Be Sufficient To Fund Operations Into Q1 Of 2025Benzinga Newsdesk - Mar 25, 2024, 4:04PM
- eFFECTOR Therapeutics Q4 EPS $(3.42) Misses $(1.65) EstimateHappy Mohamed - Mar 25, 2024, 4:02PM
Friday, March 08, 2024
Tuesday, February 06, 2024
Thursday, January 25, 2024
Wednesday, January 24, 2024
Friday, January 12, 2024
Thursday, January 11, 2024
Tuesday, January 09, 2024
- Dow Tumbles Over 200 Points; US Trade Gap Narrows In NovemberAvi Kapoor - Jan 9, 2024, 9:40AM
- eFFECTOR Therapeutics shares are trading lower after the company announced a 1-for-25 reverse stock split.Benzinga Newsdesk - Jan 9, 2024, 9:16AM
- eFFECTOR Therapeutics Announces 1-For-25 Reverse Stock Split, Will Become Effective At 12:01 A.M. Eastern Time, On January 12, 2024.Benzinga Newsdesk - Jan 9, 2024, 8:10AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Jan 9, 2024, 8:06AM
Monday, January 08, 2024
Monday, December 11, 2023
Friday, December 08, 2023
- eFFECTOR Therapeutics Discloses Updated Data From Mid-Stage Breast Cancer StudyVandana Singh - Dec 8, 2023, 11:43AM
- eFFECTOR Therapeutics Announces New Interim Data From Dose Escalation And Phase 2 Expansion Cohorts Of Zotatifin In ER+ Metastatic Breast Cancer PatientsBenzinga Newsdesk - Dec 8, 2023, 8:16AM
Thursday, November 30, 2023
Tuesday, November 28, 2023
Friday, November 24, 2023
Wednesday, November 15, 2023
Tuesday, November 14, 2023
Monday, November 13, 2023
- eFFECTOR Therapeutics Q3 EPS $(0.13) Misses $(0.12) EstimateBenzinga Newsdesk - Nov 13, 2023, 5:41PM
- Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day SessionLisa Levin - Nov 13, 2023, 1:08PM
- Why StoneCo Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving PremarketLisa Levin - Nov 13, 2023, 8:24AM
Tuesday, September 12, 2023
Thursday, August 24, 2023
- eFFECTOR Stock To Rally Over 500%? Analyst Predict Blockbuster Status For Cancer CandidatesVandana Singh - Aug 24, 2023, 2:18PM
- Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2023Benzinga Insights - Aug 24, 2023, 11:00AM
- HC Wainwright & Co. Initiates Coverage On eFFECTOR Therapeutics with Buy Rating, Announces Price Target of $5Benzinga Newsdesk - Aug 24, 2023, 6:18AM